Dupixent was approved for treating COPD with raised blood eosinophils in the EU in July 2024. Dupixent was also approved for the COPD indication in China last week. Sanofi’s stock has gained 16.0% so ...

The following is a summary of “Comparative Effectiveness of qSOFA, CURB-65, and PSI in Predicting Pneumonia Hospitalization ...

The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.

Ohtuvayre (ensifentrine) is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase three and phosphodiesterase 4 (“PDE3 and PDE4”) that combines bronchodilator and non-steroidal ...

In adults with undiagnosed respiratory symptoms, dyspnea impact was worse in those with PRISm vs undiagnosed asthma or COPD.

The mission of Blessed Home Health Care in Oregon is to provide health services to patients in the comfort and dignity of ...

Analyst Julian Harrison of BTIG maintained a Buy rating on Apogee Therapeutics, Inc. (APGE – Research Report), with a price target of ...

Hurricane Helene's​ massive rains and flooding is a major health and safety risk for residents exposed to potential ...

The global chronic disease management market size is estimated to be worth USD 5.57 billion in 2024 and is projected to reach ...

Joseph, 26, spent 24 hours in hospital last Christmas but believes the consequences may have been even worse if he had not ...